Israel's IceCure Medical H1 revenue rises on higher system, probe sales

Icecure Medical

12/08/2026 13:41

Overview
Israel cryoablation device maker's H1 2026 revenue grew 45% yr/yr
Company expanded U.S. commercial footprint with 70% growth in active installed base
Company ended H1 2026 with $12 mln in cash after multiple financings

Outlook
Company expects continued investment in U.S. commercial organization and international expansion
IceCure plans to expand CHoICE Study to more U.S. clinical sites and increase patient enrollment
Company anticipates growing physician adoption and broader commercialization of ProSense system

Result Drivers
SYSTEM AND PROBE SALES - Co said revenue growth was driven by increased sales of ProSense systems and disposable probes, reflecting both new customer adoption and higher utilization across existing accounts
U.S. INSTALLED BASE EXPANSION - Co said 70% growth in active U.S. installed base after FDA clearance contributed to higher procedure volumes and more active customer accounts
COMMERCIAL AND CLINICAL REINFORCEMENT - Co said commercial adoption is generating additional clinical evidence, while clinical activity is simultaneously driving commercial utilization and physician confidence

Company press release: ID:nPn2b8D9Na

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
$1.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Icecure Medical Ltd is $30.00, about 754.7% above its August 11 closing price of $3.51

Reuters Recommended Reads
Aug 12 - Israel's BrainsWay Q2 revenue rises 35% to record high on higher shipments, utilization
Aug 12 - Israel's Kamada Q2 revenue beats estimates on KEDRAB growth
Aug 11 - Stereotaxis Q2 revenue misses estimates, dragged by system decline

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)